COVID-19 interstitial pneumonia: monitoring the clinical course in survivors

[1]  S. Stanojevic,et al.  Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens. From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Society–coordinated Task Force , 2020, Annals of the American Thoracic Society.

[2]  B. Song,et al.  Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review , 2020, European Radiology.

[3]  Pulmonary function of patients with 2019 novel coronavirus induced-pneumonia: a retrospective cohort study. , 2020, Annals of palliative medicine.

[4]  J. Milanowski,et al.  CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. , 2020, European journal of cancer.

[5]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[6]  J. Lessler,et al.  Estimating the burden of SARS-CoV-2 in France , 2020, Science.

[7]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[8]  D. Greenwood,et al.  LONG-TERM CLINICAL OUTCOMES IN SURVIVORS OF CORONAVIRUS OUTBREAKS AFTER HOSPITALISATION OR ICU ADMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF FOLLOW-UP STUDIES , 2020, medRxiv.

[9]  J. Cashy,et al.  Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[11]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[12]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[13]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[14]  J. Lessler,et al.  Estimating the burden of SARS-CoV-2 in France , 2020, Science.

[15]  L. Einhorn,et al.  Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153). , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Xiao-Neng Mo,et al.  Abnormal pulmonary function in COVID-19 patients at time of hospital discharge , 2020, European Respiratory Journal.

[17]  Haibo Xu,et al.  Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia , 2020, Korean journal of radiology.

[18]  Anthony K. P. Jones,et al.  Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. , 2020, Journal of rehabilitation medicine.

[19]  A. Wells,et al.  Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy , 2020, The Lancet Respiratory Medicine.

[20]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[21]  Hui Chen,et al.  CT imaging changes of corona virus disease 2019(COVID-19): a multi-center study in Southwest China , 2020, Journal of Translational Medicine.

[22]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[23]  L. Billingham,et al.  Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. , 2020, The Lancet. Respiratory medicine.

[24]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.